• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invesco Nasdaq Biotechnology ETF (NQ:IBBQ)

32.71 +0.05 (+0.15%)
Streaming Delayed Price Updated: 9:39 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invesco Nasdaq Biotechnology ETF

News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
June 04, 2026
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors. 
Via The Motley Fool
Topics ETFs
News headline image
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗
November 24, 2025
AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said. 
Via Stocktwits
News headline image
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options ↗
November 20, 2025
The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said. 
Via Stocktwits
Topics Workforce
uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗
November 03, 2025
Via Stocktwits
News headline image
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally ↗
October 17, 2025
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday. 
Via Stocktwits
News headline image
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ ↗
June 12, 2025
The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease. 
Via Stocktwits
News headline image
These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy ↗
March 21, 2025
Intutive Machines specializes in lunar missions and sophisticated space technologies. These ETFs are worth looking at. 
Via Benzinga
Topics ETFs
News headline image
5 Undervalued ETFs To Ride On Powell's Market Optimism ↗
March 20, 2025
Here are five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market. 
Via Talk Markets
Topics ETFs
News headline image
Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now ↗
January 23, 2025
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗
August 19, 2024
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
News headline image
Time For Gilead Sciences-Heavy ETFs? ↗
September 12, 2023
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
News headline image
Biotech ETFs Pop On M&A Resurgence ↗
May 10, 2023
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). 
Via Talk Markets
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
News headline image
Should You Buy Biotech ETFs Now? ↗
June 16, 2021
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap